Fig. 2

Pipeline used for variants’ selection. Three steps were carried out: Step (1) 80 variants and 58 genes related to breast cancer medicationsa ccording to the PharmGKB database were considered. Step (2) Variants selected in the previous step were overlapped with data from the available genotyping platforms in the FVG cohort: 41 variants and 32 genes were used for further analysis. Step (3) Frequencies for the 41 variants selected in step 2 were compared between FVG and EUR cohorts, resulting in a set of 13 variants. Among them, for nine variants the association was supported by a certain LOE